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points, showing an AUC = 0.89; p < 0.0005, sensitivity value of
0.807, speciﬁcity of 0.841 and kappa coefﬁcient of agreement
with reference clinical diagnosis of 0.65. The scale also showed
good concurrent validity with LANSS classiﬁcation of subjects;
kappa 0.61; p < 0.0005. CONCLUSION: The Spanish version of
the ID Pain questionnaire is feasible, reliable and appropriated as
a self-administered screening tool for pain with a neuropathic
component.
PAIN—Patient Reported Outcomes
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OBJECTIVES: This study was designed to capture utility values
for health states related to malignant (MP) and non-malignant
(NMP) severe chronic pain treated with intrathecal (IT) analge-
sia. METHODS: Literature review and in depth interviews with
clinical experts (n = 5) led to the development of health state
descriptions. These were deﬁned using visual analogue scale of
pain intensity (VASPI) ranges 0–40, 41–60, 61–80 and 81–100
for both MP and NMP. Additionally 8 health states representing
common adverse events associated with IT therapy were pro-
duced. A discussion guide based on the dimensions of the EQ-5D
was developed. Health states were piloted with cognitive debrief-
ing with ﬁve members of the UK general public. Time trade off
interviews were administered to the UK general public (n = 102)
to estimate utilities for the health states. A repeated measurement
model on the TTO utilities was estimated to account for intra-
patient correlation in the data. Using the predicted values from
this model, utilities were obtained for all possible VASPI scores.
RESULTS: Participants were generally well matched to the
census proﬁle of England and Wales with some small differences
in mean age, race and education. Utilities ranged from 0.84 for
VASPI 0–40 (for NMP & MP) to -0.15 and -0.20 for VASPI
81–100 (NMP & MP respectively). The values for side effects
(irrespective of the context of chronic pain) were as follows
dizziness (0.40); nausea (0.45); pruritis (0.82); confusional state
(0.41); abnormal gait (0.67); urinary retention (0.69); weight
gain (0.77) and erectile dysfunction (0.69). The results also show
a substantial decline in utility scores related to more severe VASPI
values for non-malignant, and malignant disease. CONCLU-
SION: The study shows a signiﬁcant decrement in utility moving
from less severe to more severe levels of chronic pain. The general
public recognise the very signiﬁcant impact that severe chronic
pain has on HRQL.
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OBJECTIVES: In 1975, Melzack developed the McGill Pain
Questionnaire (MPQ), which is composed of four major parts
and evaluates the quality of pain. Objective: The aim of this
study is to assess the reliability, and validity of the MPQ on a
sample of Turkish general population. METHODS: This study
used the data from a Web-based questionnaire. This has been
administered to 342 participants. RESULTS: The results indicate
that the scale is reliable (r = 0.887). Four factors with Eigen
values over one have been extracted after evaluating the factor
analysis. This has accounted for 62.3% of the variance. Corre-
lations between sensory and evaluative subscales have been low
(r = 0.436, p < 0.01), and the most positive correlation has been
seen between the miscellaneous and sensory (r = 0.656,
p < 0.01), as well as affect subscales (r = 0.601, p < 0.01). Dis-
criminate validity has been evaluated by comparing the patient
and control group’s scores. For miscellaneous (p = 0.002) and
affect (p = 0.006) subscales statistical differences have been
found. The correlations between MPQ (subscales and all scale)
and Visual Analogue Scale point has been calculated with Spear-
man correlation for divergent validity. The correlation between
VAS and Pain Rating Index for the patient group has been
moderate (rho = 0.59, p = 0.000) and low for the control group
(rho = 0.32, p = 0.000). For both groups, most strong correlation
with the Visual Analogue Scale has been seen for the affect and
evaluation subscales of MPQ. CONCLUSION: These results
support the Turkish-MPQ as a reliable and valid measure for
evaluating the quality of pain in the Turkish population. Turkish
MPQ can be used in clinical researches to follow and to evaluate
the patients.
SKIN—Clinical Outcomes Studies
PSK1
IMPACT OF SECONDARY PROPHYLACTIC USE OF
TACROLIMUS 0.1% OINTMENT ON QUALITY-OF-LIFE,
TREATMENT OUTCOMES AND COSTS IN PATIENTS WITH
MODERATETO SEVERE ATOPIC DERMATITIS
Wollenberg A1, Sidhu M2, Odeyemi IA2, Dorsch B3,
Köhne-Volland R3, Schaff M4, Ehlken B4, Berger K4
1Klinik und Poliklinik für Dermatologie und Allergologie,
Ludwig-Maximilians Universität, München, Germany, 2Astellas Pharma
Europe Ltd, Staines, Middlesex, UK, 3Metronomia Clinical Research
GmbH, München, Germany, 4MERG—Medical Economics Research
Group, München, Germany
OBJECTIVES: To evaluate the impact of secondary prophylactic
use (PU) of tacrolimus 0.1% ointment on the quality of life
(QoL), outcomes and costs in comparison to standard use (SU) of
tacrolimus 0.1% ointment in adults with moderate to severe
atopic dermatitis (AD) over one year. METHODS: Data were
generated as part of a multi-centre, pan-European, phase III
clinical trial. Patients were randomised to tacrolimus 0.1% oint-
ment (PU) or vehicle ointment (SU) twice a week, during a
12-month disease control period. In both groups disease exacer-
bations were treated with tacrolimus 0.1% ointment twice daily.
Data on health-related QoL were obtained by using SF-36 ques-
tionnaire. Based on these data, utility values were calculated by
using the algorithm by Brazier et al. 2002. Resource consump-
tion data was derived from a patient questionnaire and pooled to
estimate the costs using German unit cost data. RESULTS:
Seventy-ﬁve patients with PU (57% moderately affected) and 59
patients with SU (59% moderately affected) participated. The
number of disease exacerbations was 2.4 (PU) vs. 5.5 (SU)
(p = 0.0014; moderate AD) and 2.3 (PU) vs. 7.4 (SU)
(p = 0.0002; severe AD). Health-related QoL (utility values) in
PU patients increased from 0.71 to 0.79 (p = 0.0014; moderate
AD) and from 0.66 to 0.75 (p = 0.002; severe AD). In the SU arm
utility values increased from 0.69 to 0.72 (NS; moderate AD) and
from 0.67 to 0.71 (NS; severe AD). In moderately affected
patients mean (SD) total annual cost per patient in the PU arm
was €1525 (1081) vs. €1729 (1209) in the SU arm. Mean (SD)
total annual cost per patient was €2045 (2013) (PU) vs. €2904
(1,510) (SU) in the group of severely affected patients. CON-
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CLUSION: Secondary prophylactic treatment with tacrolimus
0.1% ointment is more effective, leads to cost savings and higher
QoL in comparison to standard tacrolimus 0.1% ointment use,
especially in patients with severe AD.
SKIN—Cost Studies
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OBJECTIVES: Treatment of severe Psoriasis (Pso) and Psoriasis-
Arthritis (PsA) is largely conﬁned to conventional systemic-
therapy in Germany, though authorisation of biologics greatly
enhanced the therapy-spectrum. While short- and middle-term
efﬁcacy of systemic-therapy has been shown in many clinical
studies (and is incorporated in international guidelines), knowl-
edge about long-term outcome, optimal treatment and real world
effectiveness is still missing. PsoBEST, the German registry of
systemic treatments in moderate to severe Pso and PsA starts in
2007 and will document the long-term course of patients ﬁrst
entrained to a biologic or conventional systemic. Objectives are
the observation and analysis of following outcomes of systemic
antipsoriatrics authorisized: Effectiveness of real world, long-
term, combined/alternating treatments and under comorbidity
conditions. Patient-deﬁned beneﬁts, maintenance dosages, pre-
diction of response and safety. METHODS: A nationwide sample
of initially 250 (long-term approx. 500) dermatologic practices/
hospital ambulances with expertise in systemic and biologic
treatment will enrol patients consecutively. Patients will remain
in the registry for 5 years, regardless of subsequential therapy.
Study phase 1 will cover n = 3500 patients in 7 cohorts, for
which recruitment will be continued up to n = 500. Documenta-
tion will comprise patient/treatment characteristics, clinical
parameters, patient-deﬁned beneﬁt (PBI), quality of life and
adverse events. Standardized questionnaires are provided to
patients and practitioners 12 times at the dermatologic centres
and 9 times postal at interim intervals (patients residence).
Requirements of Volume 9a (EMEA) and of relevant interna-
tional guidelines on outcomes research in observational studies
are incorporated. PsoBest is aligned to planned EU-registries
(GB, N, S, E and F), relevant endpoints are comparable. Scientiﬁc
quality is assured by an interdisciplinary advisory board, AWMF,
EMEA and BfArM involvement/consultation and certiﬁcation by
DIN ISO 9001:2000. Descriptive reports will be generated regu-
larly, hypotheses will be tested e.g. by MAN(C) OVA, multiple/
logistic/ survival regression and multilevel modelling.
Comparisons between cohorts will be achieved by propensity
score matching.
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OBJECTIVES: To compare annual costs of anti-TNF therapies in
patients with psoriasis (PsO). METHODS: A decision-model was
created using TreeAge software, with clinical trial data and
average sales price (ASP) +6% (2Q 2007) for drug costs. Two
treatment strategies were compared: etanercept ﬁrst then switch-
ing to inﬂiximab and inﬂiximab ﬁrst then switching to etaner-
cept. The model assumed patients who failed to achieve Psoriasis
Area and Severity Index (PASI)-50 would switch to the other
biologic after 24 weeks. The efﬁcacy rates after switching were
assumed to be the same as the ﬁrst-line treatment. A sensitivity
analysis reducing the efﬁcacy rates after switching by 10%-30%
was conducted. The cost of adverse events was not included in
the model. Infusion fees ($237.92/infusion–2Q 2007) were
included for inﬂiximab. RESULTS: With inﬂiximab, 90% of
patients achieved PASI-50 at week-24 and continued receiving
inﬂiximab. Patients (10%) who failed to achieve PASI-50
were switched to etanercept. With etanercept, 77% of patients
achieved PASI-50 at week-24 and continued etanercept
treatment. Patients (23%) who failed to achieve PASI-50 were
switched to inﬂiximab. The etanercept-ﬁrst strategy costs
$22,113 annually and results in an overall efﬁcacy rate of 78.5%
and a cost-efﬁcacy (CE) of $28,171. The inﬂiximab-ﬁrst strategy
costs $23,544 annually and results in an 89.4% efﬁcacy rate and
a CE of $26,351. Compared with etanercept, the inﬂiximab-ﬁrst
strategy costs $1820 less per PASI-50 response. The incremental
CE ratio per PASI-50 was $13,190. The sensitivity analysis indi-
cated that the results are robust and in the same direction as the
original assumption. CONCLUSION: This decision model dem-
onstrates that an inﬂiximab-ﬁrst strategy is more cost-effective
than an etanercept-ﬁrst strategy in the treatment of psoriasis.
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